Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by RPINVESTOR1on Sep 15, 2020 8:58am
107 Views
Post# 31558886

RE:RE:RE:News Release

RE:RE:RE:News ReleaseHi Ingiboy:-

Looking back on the Replicel saga, I believe this is a story of a CEO who is not up to the assignment. The main responsibility of this CEO is to negotiate partnerships to further the trials of the hair, skin and tendon treatments. CEO 'Denbrecker' has only secured one partnership in 5 years. I give him a grade of 'F.' The key to this Company was to get a partnership with a Western company to do Phase 2 and 3 trials for RCH-01. This would have then given Shiseido a better feeling towards their relationship with Replicel.

Other responsibilities of this CEO include cash management, the commitment to not dilute the share count and being transparent with the shareholders. I give the CEO a 'D' on cash management. Money was raised mainly when there was already a lot of money owing in Accounts Payable and the stock price was reflecting this situation. 'Denbrecker' should have anticipated all possible scenarios and raised as much money as possible when the stock was trading at a higher level.

I give the CEO a 'D' on the commitment to not dilute the share count. Until recently, I would have given 'Denbrecker' a 'B.' However, this last desperate offering has caused me to downgrade his performance.

On being transparent to the shareholders, I wish there was a grade lower than 'F.' However there isn't. So I'll have to give 'Denbrecker' an 'F.'   

I am hoping that once his employment contract comes to an end we can show 'Denbrecker' the door without any additional costs to the Company. It is a mistake to hire a boy to do a man's job! 
Bullboard Posts